Khandwa Bio-Tech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 16 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 97.76%
(FY 2023)
- Ebitda 98.09%
(FY 2023)
- Net Worth -2.12%
(FY 2023)
- Total Assets -5.97%
(FY 2023)
About Khandwa Bio-Tech
The Company is engaged in the Energy And Power Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjiv Bansal, Mahendra Bora, and Parkash Chand serve as directors at the Company.
- CIN/LLPIN
U24124MP2008PTC021017
- Company No.
021017
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Aug 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Khandwa Bio-Tech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjiv Bansal  | Additional Director | Current | |
| Mahendra Bora | Additional Director | 14-Feb-2024 | Current |
| Parkash Chand | Additional Director | Current |
Financial Performance and Corporate Structure Insights of Khandwa Bio-Tech.
Khandwa Bio-Tech Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 97.76% increase in profit. The company's net worth dipped by a decrease of 2.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Khandwa Bio-Tech?
In 2023, Khandwa Bio-Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Gainhigh Capital Investments Private LimitedActive 8 years 6 months
Sanjiv Bansal and Mahendra Bora are mutual person
Praveen Securities And Investments Private LimitedActive 33 years 7 monthsSanjiv Bansal, Mahendra Bora and 1 more are mutual person
- Bansal Hospital And Research Centre Priv Ate LimitedActive 32 years 8 months
Sanjiv Bansal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Khandwa Bio-Tech?
Unlock and access historical data on people associated with Khandwa Bio-Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Khandwa Bio-Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Khandwa Bio-Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
